{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:58:44Z","timestamp":1789016324301,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1038\/s41375-021-01373-4","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T12:05:15Z","timestamp":1628510715000},"page":"3017-3020","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1401-6105","authenticated-orcid":false,"given":"J. R.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6850-9706","authenticated-orcid":false,"given":"Y-V","family":"Le Bihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9361-0283","authenticated-orcid":false,"given":"C.","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-6254","authenticated-orcid":false,"given":"B. A.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9416-7818","authenticated-orcid":false,"given":"C. P.","family":"Wardell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. F.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. H.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. E.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-6360","authenticated-orcid":false,"given":"G. J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-0028","authenticated-orcid":false,"given":"C.","family":"Pawlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"key":"1373_CR1","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/leu.2013.315","volume":"28","author":"A Thakurta","year":"2014","unstructured":"Thakurta A, Gandhi AK, Waldman MF, Bjorklund C, Ning Y, Mendy D, et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia. 2014;28:1129\u201331.","journal-title":"Leukemia"},{"key":"1373_CR2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1182\/blood.2020007081","volume":"137","author":"S Gooding","year":"2021","unstructured":"Gooding S, Ansari-Pour N, Towfic F, Ortiz Est\u00e9vez M, Chamberlain PP, Tsai KT, et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021;137:232\u20137.","journal-title":"Blood"},{"key":"1373_CR3","doi-asserted-by":"crossref","unstructured":"Donovan KA, An J, Nowak RP, Yuan JC, Fink EC, Berry BC, et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife. 2018;7:e38430.","DOI":"10.7554\/eLife.38430"},{"key":"1373_CR4","doi-asserted-by":"crossref","unstructured":"Liu J, Song T, Zhou W, Xing L, Wang S, Ho M, et al. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia. 2018;33:171\u2013180.","DOI":"10.1038\/s41375-018-0205-y"},{"key":"1373_CR5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2018-01-821769","volume":"132","author":"QL Sievers","year":"2018","unstructured":"Sievers QL, Gasser JA, Cowley GS, Fischer ES, Ebert BL. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4(CRBN) activity. Blood. 2018;132:1293\u2013303.","journal-title":"Blood"},{"key":"1373_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61027-w","volume":"10","author":"S Tateno","year":"2020","unstructured":"Tateno S, Iida M, Fujii S, Suwa T, Katayama M, Tokuyama H, et al. Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide. Sci Rep. 2020;10:4012.","journal-title":"Sci Rep."},{"key":"1373_CR7","doi-asserted-by":"crossref","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins. Science. 2013;343:305\u20139.","DOI":"10.1126\/science.1244917"},{"key":"1373_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301\u20135.","journal-title":"Science"},{"key":"1373_CR9","doi-asserted-by":"crossref","unstructured":"Sievers QL, Petzold G, Bunker RD, Renneville A, Slabicki M, Liddicoat BJ, et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science. 2018;362:eaat0572.","DOI":"10.1126\/science.aat0572"},{"key":"1373_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0173-0","volume":"9","author":"YX Zhu","year":"2019","unstructured":"Zhu YX, Shi CX, Bruins LA, Wang X, Riggs DL, Porter B, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019;9:19.","journal-title":"Blood Cancer J"},{"key":"1373_CR11","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326\u201335.","journal-title":"Leukemia"},{"key":"1373_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57\u201373.","journal-title":"Lancet Oncol"},{"key":"1373_CR13","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3324\/haematol.2018.202200","volume":"104","author":"JR Jones","year":"2019","unstructured":"Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, et al. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica. 2019;104:1440\u201350.","journal-title":"Haematologica"},{"key":"1373_CR14","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1074\/jbc.M117.816868","volume":"293","author":"AA Akuffo","year":"2018","unstructured":"Akuffo AA, Alontaga AY, Metcalf R, Beatty MS, Becker A, McDaniel JM, et al. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem. 2018;293:6187\u20136200.","journal-title":"J Biol Chem"},{"key":"1373_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/jmedgenet-2016-104117","volume":"54","author":"A Sheereen","year":"2017","unstructured":"Sheereen A, Alaamery M, Bawazeer S, Al Yafee Y, Massadeh S, Eyaid W. A missense mutation in the. J Med Genet. 2017;54:236\u201340.","journal-title":"J Med Genet"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01373-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01373-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01373-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T13:25:37Z","timestamp":1632835537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01373-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1373"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01373-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,9]]},"assertion":[{"value":"20 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JRJ: Celgene Corporation-honoraria, research funding. MFK: Chugai-consultancy; Bristol-Myers Squibb, Takeda\u2013consultancy, travel support; Janssen, Amgen\u2013consultancy, honoraria; Celgene Corporation\u2013consultancy, honoraria, research funding. GHJ: Roche, Amgen, Janssen, Merck Sharp, and Dohme\u2013consultancy, honoraria, speakers bureau; Celgene Corporation, Takeda\u2013consultancy, honoraria, travel support, research funding, speakers bureau. FED: Adaptive\u2013honoraria; Celgene Corporation\u2013consultancy, honoraria, research funding; Janssen, Oncopeptide, Roche, Sanofi, Takeda\u2013consultancy, honoraria. RC: Celgene Corporation\u2013previous employment, Monte Rosa Therapeutics - founder. GJM: Janssen\u2013research funding; Bristol-Myers Squibb, Takeda, Roche, Amgen, GSK, Karyopharm\u2013consultancy, honoraria; Celgene Corporation\u2013consultancy, honoraria, research funding. CP: Amgen, Takeda\u2013consultancy, travel support; Janssen\u2013honoraria, travel support; Celgene Corporation\u2013consultancy, honoraria, travel support; Sanofi\u2013consultancy, honoraria. The ICR has a financial interest in the development of compounds targeting CRL4-CRBN E3-ubiquitin ligase. YVLB, HW, RC, CP are involved in collaborative projects with Monte Rosa Therapeutics. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}